Introduction {#s1}
============

Over the past 40 years, scientists have devoted themselves to understanding the enzymes that can hydrolyze the *sn*-2 ester bond of phospholipids to release free fatty acids [@pone.0059267-Dennis1], leading to the discovery of the phospholipase A~2~ (PLA~2~) superfamily. The free fatty acids released by PLA~2~ can be converted to eicosanoids, including the prostaglandins and leukotrienes, which are involved in inflammatory responses [@pone.0059267-Buczynski1]. So far, six types including sixteen distinct groups of PLA~2~ have been identified ([Table 1](#pone-0059267-t001){ref-type="table"}). The three main types of PLA~2~, secreted PLA~2~ (sPLA~2~), cytosolic PLA~2~ (cPLA~2~) and Ca^2+^-independent PLA~2~ (iPLA~2~), were found early and are well-studied; hence several enzymes have been categorized for each type. Platelet activating factor acetylhydrolase (PAF-AH), lysosomal PLA~2~ and adipose-specific PLA~2~ (Ad-PLA~2~) were later discovered and are now part of the phospholipase A~2~ superfamily. These PLA~2~s can be differentiated by their cellular localization, Ca^2+^ dependence of the activity and their physical properties [@pone.0059267-Six1]. The activities and membrane association of sPLA~2~(s) and cPLA~2~(s) are Ca^2+^ dependent, whereas the activity of iPLA~2~, Lp-PLA~2~, lysosomal PLA~2~ and Ad-PLA~2~ are independent of Ca^2+^ [@pone.0059267-Dennis1]. The activation of these PLA~2~s have been vigorously investigated and shown to be involved in inflammation, atherosclerosis, cancer, diabetes and neurodegenerative diseases.
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###### The phospholipase A~2~ superfamily.

![](pone.0059267.t001){#pone-0059267-t001-1}

  Type                                  Group           Subgroups            Size (kDa)   Ca^2+^   Cellular Location   Catalytic Residues
  ------------------------------------ ------- ---------------------------- ------------ -------- ------------------- --------------------
                                         GI                A, B                13--15                                 
                                         GII         A, B, C, D, E, F          13--17                                 
                                        GIII                                   15--18                                 
                                         GV                                      14                                   
  sPLA~2~                                GIX                                     14        Yes         Secreted             His/Asp
                                         GX                                      14                                   
                                         GXI                                   12--13                                 
                                        GXII                                     19                                   
                                        GXIII                                   \<10                                  
                                        GXIV                                   13--19                                 
  cPLA~2~                                GIV         A(α), B(β), C(γ)         60--114      Yes          Cytosol             Ser/Asp
  iPLA~2~                                GVI         A, B, C, D, E, F          84--90       No       Cytosol Mito.          Ser/Asp
  PAF-AH                                GVII    A(Lp-PLA~2~), B(PAF-AH II)     40--45       No         LDL, HDL           Ser/His/Asp
                                        GVIII         α~1~, α~2~, β            26--40                                 
  Lysosomal PLA~2~                       GXV                                     45         No         Lysosome           Ser/His/Asp
  Adipose-specific PLA~2~ (AdPLA~2~)    GXVI                                     18         No         Adipocyte            His/Cys

Adapted from Dennis et al [@pone.0059267-Dennis1].

The complex anionic phospholipid, cardiolipin, is a major component of the inner membrane of mitochondria and bacterial membranes [@pone.0059267-Pangborn1], [@pone.0059267-Hirschberg1], [@pone.0059267-Hostetler1]. Cardiolipin has been shown to be a substrate of both sPLA~2~ and cPLA~2~ utilizing a fluorescent labeled cardiolipin [@pone.0059267-Buckland1], [@pone.0059267-Marinetti1] and implied to be a substrate for iPLA~2~ [@pone.0059267-Malhotra1]. Most cardiolipin resides in mitochondria and accounts for 10--20% of the total lipid in mammalian cells. Cardiolipin is an important membrane component maintaining the integrity of mitochondria and is critical for the production of ATP via the electron transport chain [@pone.0059267-Ascenzi1], [@pone.0059267-Claypool1], [@pone.0059267-Sparagna1] by stabilizing the electron transport chain complex in the inner mitochondrial membrane [@pone.0059267-Gomez1], [@pone.0059267-Eble1]. Cardiolipin associates with the membrane-anchored cytochrome *c* under homeostatic conditions [@pone.0059267-Kalanxhi1]. Oxidative stress causes peroxidation of cardiolipin and thus, hampers the electron transport chain and alters mitochondrial bioenergetics [@pone.0059267-Paradies1], [@pone.0059267-Lesnefsky1], [@pone.0059267-Paradies2]. When programmed cell death is initiated, the interactions between cytochrome *c* and cardiolipin is disturbed [@pone.0059267-Kalanxhi1], [@pone.0059267-Ott1], [@pone.0059267-Belikova1]. Besides its functions in mitochondria, cardiolipin has been shown to be associated with several diseases. Cardiolipin causes the immune response to the anti-cardiolipin antibodies, which has been shown to be associated with increased risks of venous or arterial thrombosis and ischemic coronary and cerebral disease [@pone.0059267-Hughes1], [@pone.0059267-Harris1], [@pone.0059267-Edwards1], [@pone.0059267-Rand1]. Cardiolipin is also a significant and normal physiologic component present in human plasma lipoproteins including LDL and HDL [@pone.0059267-Deguchi1]. Recently, cardiolipin release from damaged mitochondria has been shown to exacerbate breathing problems of pneumonia patients [@pone.0059267-Ray1]. Uniquely and more importantly, cardiolipin is a substrate for the PLA~2~ superfamily of enzymes; however, their activities *in vitro* have not yet been characterized.

An X-linked tafazzin gene mutation causes the alterations of mitochondrial cardiolipin, including modified acyl chains and accumulation of monolyso-cardiolipin, and with a deficiency in cardiolipin remodeling, many patients further develop Barth syndrome. [@pone.0059267-Malhotra1], [@pone.0059267-Valianpour1], [@pone.0059267-Vreken1]. The 85-kDa GVIA iPLA~2~ (also known as iPLA~2~β) has been shown to localize to mitochondria in many types of cells [@pone.0059267-Gadd1], [@pone.0059267-Liou1], [@pone.0059267-Seleznev1], [@pone.0059267-Song1], which indicates iPLA~2~ is localized in the proximity of cardiolipin. iPLA~2~ was characterized and it showed potent phospholipase, lysophospholipase and transacylase activities toward phosphatidylcholine (PC) which could be blocked by various inhibitors [@pone.0059267-Ackermann1], [@pone.0059267-Lio1], [@pone.0059267-Lio2], [@pone.0059267-Hazen1]. iPLA~2~ has been suggested to be responsible for cardiolipin deacylation and monolyso-cardiolipin accumulation in Barth syndrome and hypertensive heart failure [@pone.0059267-Malhotra1], [@pone.0059267-Zachman1]. Inhibition of iPLA~2~ can suppress the phenotype of tafazzin knockouts in drosophila [@pone.0059267-Malhotra1]. The discovery that cardiolipin is involved in Barth syndrome has suggested that the catabolism of cardiolipin by PLA~2~ plays a pivotal role in mitochondria maintenance. iPLA~2~ inhibition could be a potential treatment for Barth syndrome patients.

Because radiolabeled cardiolipin is challenging to synthesize, our goal in this study was to develop a mass spectrometry methodology to quantitate PLA~2~ activity toward natural and synthetic non-radiolabeled cardiolipin and further understand the activity of PLA~2~ toward cardiolipin. We utilized mass spectrometry (GC/MS and LC/MS) to monitor hydrolysis of cardiolipin by the four major types of PLA~2~, including GI and GV sPLA~2~, cPLA~2~, iPLA~2~ and Lp-PLA~2~ and also determined whether the hydrolysis occurs at the *sn*-1 and/or *sn*-2 positions. Additionally, we obtained further information regarding the interfacial catalytic activities of these PLA~2~ enzymes.

Materials and Methods {#s2}
=====================

Materials {#s2a}
---------

Natural and synthetic cardiolipin and 1-palmitoyl-2-arachidonoyl-*sn*-phosphatidylcholine (PAPC) were from Avanti Polar Lipids. 1-palmitoyl-2-arachidonyl- \[arachidonyl-1-^14^C\]--phosphatidylcholine was purchased from Perkin Elmer. All other reagents were analytical reagent grade or better.

PLA~2~ Activity Assay {#s2b}
---------------------

For the basal specific activity of PLA~2~, assays were performed in a buffer composed of 100 mM HEPES at pH 7.5. The mixed micelles were composed of 0.1 mM PAPC (containing ^14^C labeled PAPC with 80,000 cpm) and 0.4 mM Triton X-100 in a final volume of 500 µl. Different compositions of lipid mixed-micelles containing PAPC, cardiolipin and PI(4,5)P~2~ were mixed and dried, and then prepared utilizing the same method. ATP, Ca^2+^ and DTT were added depending on the requirement of the particular PLA~2~. GIA sPLA~2~ and GV sPLA~2~ assays were carried out in 5 mM Ca^2+^; GIVA cPLA~2~ assays were carried out in 3% PI(4,5)P~2~, 2 mM DTT and 0.1 mM Ca^2+^, and GVIA iPLA~2~ assays were carried out in 1 mM EDTA, 2 mM ATP and 4 mM DTT. The reaction was initiated by adding PLA~2~ to mixed micelles and incubated at 40°C for 30 min. After incubation, the reaction was quenched, and the fatty acids were extracted using a modified Dole assay protocol as previously described [@pone.0059267-Barbayianni1], [@pone.0059267-Kokotos1].

Fatty Acid Analysis by GC/MS {#s2c}
----------------------------

For GC/MS analysis, the deuterated internal standards were added before fatty acid extraction for the calibration of extraction efficiency and handling errors. The free fatty acids were analyzed as their pentafluorobenzyl (PFB) bromide derivatives in negative ionization mode [@pone.0059267-Pawlosky1]. The extracted free fatty acids were taken up in 25 µl of 1% diisopropylethylamine in acetonitrile and derivatized with 25 µl 1% PFB bromide in acetonitrile at room temperature for 20 min in capped glass tubes. The solvent was removed by vacuum evaporator, the residue was dissolved in 50 µl isooctane, and 1 µl of the PFB esters was analyzed by GC electron capture MS (GC/EC/MS). The fatty acid esters dissolved in 50 µl isooctane were injected (1 µl) into an Agilent 6890N gas chromatograph equipped with an Agilent 7683 auto-sampler (Santa Clara CA). The amounts of fatty acids were quantitated by the standard curve between 500 µg and 0.05 µg of fatty acids. Extraction and ionization efficiencies were determined for the internal standards by comparing the ion intensity of the samples with those of the extraction controls. The range of efficiency for a typical experiment was between 20 and 75%, with an average of around 50%. PLA~2~ activities were calculated by the amount of quantified fatty acids.

Cardiolipin, 1′,3′-Bis-\[1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho\]-sn-glycerol, and its PLA~2~ hydrolysis products, monolyso-cardiolipin and dilyso-cardiolipin were purified by Bligh and Dyer lipid extraction methods [@pone.0059267-Bligh1]. The extracted cardiolipin, monolyso-cardiolipin and dilyso-cardiolipin were dried with nitrogen gas at room temperature. Samples were resuspended in 50% solvent A (water-acetonitrile- acetic acid; 70/30/0.02, v/v/v), and 50% solvent B (acetonitrile-isopropyl alcohol; 50/50, v/v). The cardiolipin sample was then injected into a tandem quadrupole mass spectrometer (ABI 4000 Q-Trap MS) by the direct infusion technique. The cardiolipin was analyzed via MS and precursor ion in negative ion mode. The electrospray voltage was −4.5 kV, and the turbo ion spray source temperature was 525°C. The precursor ions of oleic acid (m/z = 281.4) used nitrogen as a collision gas. The cardiolipin (m/z = 728.2), the monolyso-cardiolipin (m/z = 596.4) and the dilyso-cardiolipin (m/z = 463.9) were monitored in the negative mode during a precursor scan experiment.

Results and Discussion {#s3}
======================

PLA~2~ Activity Toward Cardiolipin {#s3a}
----------------------------------

Cardiolipin has been shown to be a substrate for both cPLA~2~ and sPLA~2~ using fluorescence labeling substrate [@pone.0059267-Buckland1]. This indicates that the phospholipid *sn*-2 position can be recognized by phospholipase A~2~, despite its unique structure containing four fatty acyl chains with a bulky and negatively charged head group ([Fig. 1](#pone-0059267-g001){ref-type="fig"}). Whether cardiolipin is also a substrate for iPLA~2~ and Lp-PLA~2~ was not known. The direct measurement and comparisons of the PLA~2~ activity by following fatty acid hydrolysis has not been reported. Here we showed that the hydrolysis of tetraoleoyl(18∶1)-cardiolipin can be monitored by measuring the oleic acid released by both GC/MS and LC/ESI-MS/MS ([Fig. 2](#pone-0059267-g002){ref-type="fig"}) without fluorescent or radio-labeling. Three common contaminants from single-use glassware during fatty acid derivatization, 16∶0, 18∶2 and 18∶0 do not affect the quantification of 18∶1 on GC/MS. Because oleic acid (18∶1) is the most abundant fatty acyl chain in the biological samples, measurement of the oleic acid release is the best way to quantify cardiolipin hydrolysis. The advantage of the oleic acid measurement on LC-MS/MS is to avoid those fatty acid contaminants and the oleic acid peak can be isolated in the precursor mode.

![Structure of Cardiolipin.\
The structure of cardiolipin, 1′,3′-Bis-\[1, 2-di-(9Z-octadecenoyl)-sn-glycero-3-phopho\]-*sn*-glycerol, is drawn and adapted from LIPID MAPS ([www.lipidmaps.org](http://www.lipidmaps.org)).](pone.0059267.g001){#pone-0059267-g001}

![Cardiolipin Hydrolysis by iPLA~2~.\
A. GC/MS analysis of the free fatty acids released from cardiolipin by hydrolysis with (red) and in the absence of (blue) iPLA~2~. B. The main mass peak released by iPLA~2~ at 8.0 min on GC is oleic acid (18∶1). C. LC/MS analysis of the main fatty acid released from cardiolipin hydrolysis by iPLA~2~.](pone.0059267.g002){#pone-0059267-g002}

We further examined the cardiolipin activities of five different PLA~2~ enzymes representing four different PLA~2~ types by GC mass spectrometry ([Fig. 3](#pone-0059267-g003){ref-type="fig"}). The activities of these five highly purified enzymes, GVIA iPLA~2~, GIA sPLA~2~, GV sPLA~2~, GIVA cPLA~2~ and Lp-PLA~2~ have been well characterized previously [@pone.0059267-Barbayianni1], [@pone.0059267-Kokotos1]. The results show that cardiolipin is a substrate for GVIA iPLA~2~, GIA sPLA~2~, GV sPLA~2~ and GIVA cPLA~2~, but not Lp-PLA~2~. The specific activities are 2.0 µmol/min/mg for GVIA iPLA~2~, 36.9 µmol/min/mg for GIA sPLA~2~, 5.0 µmol/min/mg for GV sPLA~2~ and 2.3 µmol/min/mg for GIVA cPLA~2~. The negatively charged PI(4,5)P~2~ binds to cPLA~2~ in a 1∶1 stoichiometry to increase its enzymatic activity [@pone.0059267-Mosior1]. A lysine pocket in the catalytic domain (Lys488, Lys541, Lys543, and Lys544) was shown to be essential for PIP~2~-dependent activity increases [@pone.0059267-Six2]. PIP~2~ therefore was recognized as an activator of cPLA~2~ and was included in the standard assay. Without PIP~2~ in the cardiolipin assay, GIVA cPLA~2~ showed an activity of 1.4 µmol/min/mg, consistent with the activation of cPLA~2~ by PIP~2~, though less so than with PAPC as substrate, suggesting perhaps that PIP~2~ may have less impact on the negatively charged surface of cardiolipin. Interestingly, GIA sPLA~2~ purified from snake venom shows the highest activity among all PLA~2~s. The sPLA~2~ in the snake venom can cause excessive inflammation when added to tissues through the hydrolysis of phospholipid membranes [@pone.0059267-Damerau1], [@pone.0059267-Cirino1].

![PLA~2~s Specific Activities toward Cardiolipin.\
The activities of GVIA iPLA~2~, GIA sPLA~2~, GV sPLA~2~, GIVA cPLA~2~ and Lp-PLA~2~, toward cardiolipin were examined by GC mass spectrometry. cPLA~2~ activities both with and without PIP~2~ activation are shown.](pone.0059267.g003){#pone-0059267-g003}

Lyso-cardiolipin Analysis by LC/MS {#s3b}
----------------------------------

The unique structure and the negative charge of cardiolipin stabilize the electron transport chain complex and maintain the structure of mitochondria membranes. Hydrolysis of cardiolipin will inevitably affect the structure and function of mitochondria. We have demonstrated that cardiolipin is a substrate for sPLA~2~, cPLA~2~ and iPLA~2~ ([Fig. 2](#pone-0059267-g002){ref-type="fig"}). The hydrolysis of cardiolipin should generate lyso-cardiolipin products and we employed tandem mass spectrometry to monitor the production of these species ([Fig. 4](#pone-0059267-g004){ref-type="fig"}).

![Cardiolipin and Lyso-cardiolipin Analysis by LC/MS.\
A. The dominant cardiolipin (18∶1) peak in mass spectrometry was observed as a doubly charged ion in the negative ion mode. B. Cardiolipin was hydrolyzed by iPLA~2~ in a mixed-micelle assay and the cardiolipin was extracted by the Bligh/Dyer method and then analyzed by LC/MS. C. GIA sPLA~2~ hydrolysis of cardiolipin results in the accumulation of mainly dilyso-cardiolipin.](pone.0059267.g004){#pone-0059267-g004}

The dominant fatty acyl on cardiolipin (18∶1) peak in mass spectrometry is seen as a doubly charged ion in the negative mode ([Fig. 4A](#pone-0059267-g004){ref-type="fig"}). These two negative charges of cardiolipin are from the two negative charges on the phosphate groups. The cardiolipin was hydrolyzed by iPLA~2~ in a mixed-micelle assay and the cardiolipin was extracted by the Bligh/Dyer method and then analyzed by LC/ESI-MS/MS ([Fig. 4B](#pone-0059267-g004){ref-type="fig"}). We identified the monolyso-cardiolipin (m/z = 596.4) and the dilyso-cardiolipin (m/z = 463.9) peaks by monitoring oleic acid (m/z = 281.4) in a precursor ion scan experiment. Both lyso-cardiolipins are also doubly charged as is cardiolipin. We have not detected any trilyso-cardiolipins, which would probably be very hydrophilic and not extracted by the current extraction method. Alternatively, iPLA~2~ may never cleave the *sn*-1 fatty acyl chain. Interestingly, sPLA~2~, which is known to have only *sn*-2 specific activity, only cleaves two fatty acyl chains off the cardiolipin resulting in the accumulation of dilyso-cardiolipin ([Fig. 4C](#pone-0059267-g004){ref-type="fig"}). This indicates the two *sn*-2 positions also have significantly higher rates of hydrolysis by PLA~2~ than the two *sn*-1 positions for sPLA~2~. We further purified the dilyso-cardiolipin from the GIA sPLA~2~ assay of cardiolipin. The hydrolyzed products have 90% dilyso-cardiolipin, which is the sn-1(1′)-diacyl-lysocardiolipin, and contain less than 10% of monolyso-cardiolipin; the latter may arise from migration of the sn-1 fatty acid to the sn-2 position as occurs with PC. Assaying the five phospholipase A~2~s for PLA~1~ activity against dilyso-cardiolipin gave no activity.

Differential PLA~2~ Activities {#s3c}
------------------------------

The presence of four sterically distinct fatty acyl chains in cardiolipin presents challenges for kinetic studies of PLA~2~ hydrolysis. These phospholipase A~2~(s) have specific activity against the two *sn*-2 fatty acyl chains, but no activity toward the *sn*-1 chains. Previously, iPLA~2~ has been reported to catalyze a transacylase reaction [@pone.0059267-Lio2]. Cardiolipin, monolyso-cardiolipin and dilyso-cardiolipin can be measured in one mass spectrometry run ([Fig. 3](#pone-0059267-g003){ref-type="fig"}). Here, we aimed at understanding how PLA~2~ hydrolyzes cardiolipin to produce lyso-cardiolipins over a 2-hour time scale.

The mixed micelle assays contained 100 µM cardiolipin and 400 µM of Triton. The cardiolipin, monolyso-, and dilyso- cardiolipin were measured in the same samples by LC-MS/MS ([Fig. 4B](#pone-0059267-g004){ref-type="fig"}). The total ion counts for all cardiolipin species were calculated in each sample. The percentages of cardiolipin and lyso-cardiolipin were determined by the ratio of the ion counts for this particular cardiolipin species to the total ion counts ([Fig. 5](#pone-0059267-g005){ref-type="fig"}). The two sPLA~2~s showed a very similar pattern with the hydrolysis of cardiolipin occurring relatively early in the assay ([Fig. 5B, C](#pone-0059267-g005){ref-type="fig"}). The production of monolyso-cardiolipin increased during the initial 20 min and then reached a plateau. Dilyso-cardiolipin production continued through the whole time course. After 60 min, the dilyso-cardiolipin became the most abundant species. On the other hand, iPLA~2~ showed a completely different pattern. The cardiolipin percentage remained above 50% and lyso-cardiolipin levels stayed below 30%. The accumulation of dilyso-cardiolipin observed in the sPLA~2~ experiments did not occur for iPLA~2~ hydrolysis. This indicates that iPLA~2~ is regulated by a different mechanism than sPLA~2~ to maintain cardiolipin and lyso-cardiolipin at constant levels.

![Differential Cardiolipin Hydrolysis by iPLA~2~ and sPLA~2~.\
The hydrolysis of cardiolipin by A. GVIA iPLA~2~, B. GIA sPLA~2~ and C. GV sPLA~2~ were examined in mixed micelle assays containing 100 µM cardiolipin and 400 µM Triton X-100 over a 100 min time course. The cardiolipin (green), monolyso- (red) and dilyso-cardiolipin (blue) were measured in the same samples by LC/MS. The percentages of cardiolipin and lyso-cardiolipin are based on ion intensity counts.](pone.0059267.g005){#pone-0059267-g005}

Cardiolipin Effects on PLA~2~ Activities {#s3d}
----------------------------------------

Cardiolipin is not only a substrate of various PLA~2~s, but it may also play a key role in regulating PLA~2~ activities at the membrane surface. The catalytic activities of PLA~2~ and phospholipid metabolism can be affected by the presence of the bulky and negatively charged cardiolipin. Hence, we have utilized an *in vitro* mixed micelle assay to determine the effect of cardiolipin on the enzymatic activities of five different PLA~2~s acting on PAPC ([Fig. 6](#pone-0059267-g006){ref-type="fig"}). 1-palmitoyl(16∶0)-2-arachidonoyl(20∶4)-*sn*-phosphatidylcholine (PAPC) was chosen because it does not interfere with the measurement of the oleic acid (18∶1) release from cardiolipin. A total of 100 µM phospholipid and 400 µM Triton X-100 was used as substrate. The results showed two major types of cardiolipin effects, activation or inhibition, on PLA~2~ activities. The inhibition by cardiolipin was observed for the activity of iPLA~2~ and cPLA~2~ toward PAPC ([Fig. 6A, D](#pone-0059267-g006){ref-type="fig"}). At 50% cardiolipin, iPLA~2~ activity was inhibited 80% and cPLA~2~ activity was inhibited 90%. The decrease caused by the addition of cardiolipin was not linear. The decreased level was higher than surface dilution of PAPC would predict assuming equal surface areas for Triton X-100, PC and cardiolipin molecules. Of course, the bulky volume of cardiolipin makes the calculation of surface dilution more complex than with simpler lipids in the PAPC/Triton X-100 mixed micelle system. In contrast, activation effects were observed with GIA and GV sPLA~2~ acting on PAPC which occurred when the phospholipid composition contained 0--20% cardiolipin ([Fig. 6B, C](#pone-0059267-g006){ref-type="fig"}). The PLA~2~ activity decreased when the cardiolipin content was above 20%. The decreased rate of activity was similar to that expected for surface dilution of the PAPC, but represents a complex mixture of effects. The maximum increase was 4 fold for both GIA sPLA~2~ and GV sPLA~2~. In the presence of 50% cardiolipin, the activity for both enzymes toward PAPC was at the same level as if cardiolipin was not added. Note that Lp-PLA~2~ did not show significant activity toward PAPC or cardiolipin confirming that it has specificity for short chain containing and/or oxidized phospholipids [@pone.0059267-Cao1].

![Cardiolipin Effects on PLA~2~ Activity toward PAPC.\
The *in vitro* mixed micelle assay was utilized to determine if cardiolipin affects the enzymatic activities of A. GVIA iPLA~2~, B. GIA sPLA~2~, C. GV sPLA~2~, and D. GIVA cPLA~2~ toward PAPC. Mixed micelles composed of 100 µM phospholipid and 400 µM Triton X-100 was employed as substrate containing the mole % of cardiolipin to PAPC indicated.](pone.0059267.g006){#pone-0059267-g006}

Because both cardiolipin and PAPC are substrates for PLA~2~, the activation or inhibition curves could be altered by a surface charge effect, a competition effect and/or a surface dilution effect, we further examined the activity differences between these two substrates ([Fig. 7](#pone-0059267-g007){ref-type="fig"}). For iPLA~2~ and cPLA~2~, the activity decreased along with the increase of cardiolipin. The activity of iPLA~2~ toward cardiolipin was 2 µmol/min/mg, which was 3.8 times higher than toward PAPC in this assay. However, cPLA~2~ showed the opposite relative activity toward cardiolipin and PAPC. Under activating conditions, GIA sPLA~2~ showed a 3 fold greater activity toward PAPC than toward cardiolipin. GV sPLA~2~ showed a higher activity toward cardiolipin (18∶1) than toward the PAPC substrate. The competition and surface dilution effects did not appear significant when the overall cardiolipin was below 20%. When cardiolipin was increased above 20%, cardiolipin became a major substrate, and then the competition between cardiolipin and PAPC became apparent. sPLA~2~ is particularly interesting in that it has high activity against cardiolipin and cardiolipin presence can increase its activity toward phosphatidylcholine. Negative charge may play a key role of the increase of activity, suggesting the hydrolysis of the cardiolipin in mitochondria may speed up the breakdown of other phospholipids by any secreted PLA~2~ generated.

![Comparison of PLA~2~ activities.\
The activities of GVIA iPLA~2~, GIA sPLA~2~, GV sPLA~2~, and GIVA cPLA~2~ toward cardiolipin (blue) and PAPC (red) are shown. The assays were conducted in mixed micelle assays containing either 100 µM cardiolipin or 100 µM PAPC and 400 µM Triton X-100. The fold differences between cardiolipin and PAPC were calculated and are shown.](pone.0059267.g007){#pone-0059267-g007}

Conclusions {#s3e}
-----------

Each of the five enzymes studied are thought to have a different physiological function and the PLA~2~ activities toward cardiolipin as a substrate are significantly different for each ([Fig. 7](#pone-0059267-g007){ref-type="fig"}). The unique structure of cardiolipin also differentially affects the PLA~2~ activities toward other phospholipids ([Fig. 6](#pone-0059267-g006){ref-type="fig"}). Two major features of cardiolipin are the large head group formed by two glycerol backbones and its two negative charges from the two phosphates. One would assume that the large head group would affect the uniform lipid surface and affect activity as seen with iPLA~2~ and cPLA~2~, but not sPLA~2~ and Lp-PLA~2~. Interestingly, cPLA~2~ and iPLA~2~ are the two enzymes with high molecular weights and both contain a regulatory domain and a catalytic domain. Even 5% cardiolipin can decrease their activity toward PC. The other complication is the surface dilution effect. The addition of cardiolipin dilutes the concentration of PAPC on the surface of the Triton X-100 mixed micelles. The inhibition toward cPLA~2~ is more significant than iPLA~2~. Note that the cPLA~2~ mixed micelle assay contains the negatively charged PIP~2~ and the surface dilution effects by cardiolipin may be enhanced by PIP~2~ dilution. On the other hand, sPLA~2~ is only affected above 20% cardiolipin. Interestingly, cardiolipin is predominantly found in mitochondria, which contains 10--20% cardiolipin. In the mixed micelle assays, the cardiolipin forms a negatively charged surface and sPLA~2~ has been shown to favor anionic phospholipid substrates. The increased affinity toward the anionic surface may play an important role. The surface dilution effect starts to take place and decrease the PLA~2~ activities when the cardiolipin content is above 20% in the GIA and GV sPLA~2~ assays. Overall, cardiolipin alters membrane dynamics, which affects these different enzymes binding to micelles and catalyzing lipid hydrolysis. The fatty acid composition at the *sn*-2 positions may also be a factor. Among these enzymes, sPLA~2~ and iPLA~2~ do not have much specificity for the specific fatty acid while cPLA~2~ is selective for arachidonic acid and Lp-PLA~2~ is very specific for short fatty acyl chains and oxidized fatty acids. Because the availability of commercial cardiolipins with different fatty acyl composition is limited at this time, we cannot yet address the specificity further.
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